BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.76M | 1.56M | 1.63M | 1.60M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.32M | 8.55M | 6.33M | 7.17M | 5.15M |
| Operating Income | -8.32M | -8.55M | -6.33M | -7.17M | -5.15M |
| Income Before Tax | -8.28M | -8.16M | -6.22M | -6.34M | -5.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.28M | -8.16M | -6.22M | -6.34M | -5.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 80.80K | 72.70K | 98.00K | 46.40K | 27.10K |
| Net Income | -8.20M | -8.09M | -6.13M | -6.29M | -5.80M |
| EBIT | -8.32M | -8.55M | -6.33M | -7.17M | -5.15M |
| EBITDA | -8.30M | -8.53M | -6.30M | -7.14M | -5.13M |
| EPS Basic | -4.35 | -9.23 | -16.40 | -23.31 | -32.67 |
| Normalized Basic EPS | -2.73 | -5.78 | -10.15 | -14.50 | -20.36 |
| EPS Diluted | -4.35 | -9.24 | -16.40 | -23.31 | -32.67 |
| Normalized Diluted EPS | -2.73 | -5.78 | -10.15 | -14.50 | -20.36 |
| Average Basic Shares Outstanding | 1.88M | 877.10K | 373.60K | 270.00K | 177.60K |
| Average Diluted Shares Outstanding | 1.88M | 877.10K | 373.60K | 270.00K | 177.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |